BioCentury
ARTICLE | Clinical News

IDM presents interim NSCLC Phase II data

June 5, 2007 2:12 AM UTC

IDM Pharma (IDMI) presented interim results from a Phase II trial of EP-2101 to treat stage IIIB/IV or recurrent non-small cell lung cancer in HLA-A2-positive patients. In the open-label trial in a total of 135 patients, 60% of the 63 patients receiving EP-2101 were alive at one year with a median survival of 583 days. The comparator was a group of 72 patients with HLA-A2-negative NSCLC who were not enrolled in the study and could receive any treatment they wanted. Median survival in this group was 361 days, and 49% of patients were alive after one year. Overall survival and safety are the primary endpoints. Data were presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago. ...